Article Text

other Versions

PDF
Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration (ARMD).
  1. Rustum Karanjia (4rk11{at}queensu.ca),
  2. Kenneth T Eng (kt_eng{at}hotmail.com),
  3. Jeff Gale (jeffgaleuwo{at}yahoo.com),
  4. Sanjay Sharma (sanjay_sharma60{at}hotmail.com),
  5. Martin W ten Hove (tenhovem{at}gmail.com)
  1. Queen's University, Canada
  2. Queen's University, Canada
  3. Queen's University, Canada
  4. Queen's University, Canada
  5. Queen's University, Canada

    Abstract

    OBJECTIVE: To examine the sensitivity of mf-ERG at measuring changes in retinal electrical activity in response to Avastin (bevacizumab) treatment for age-related Macula degeneration (ARMD).

    METHODS: Nine subjects with exudative ARMD, not previously treated with bevacizumab in the investigated eye, underwent pretreatment testing with mf-ERG and intravenous fluorescein angiography (IVFA). A second mf-ERG test was conducted post-treatment. The P1 response amplitudes were examined for the hexagons corresponding to areas of pathology on the IVFA. Inter-test variability was accounted for by examining areas without pathology. Aggregate responses were also generated for central and lesion associated responses.

    RESULTS: Changes in P1 response amplitude correlated with changes in visual acuity (R2>0.96). An improvement in Snellen visual acuity correlated with a significant improvement in P1 response amplitude from lesion associated recordings (p<0.03). Changes in P1 response amplitudes were not observed when aggregate responses were generated.

    CONCLUSION: This study represents a novel method for assessing an improvement of mf-ERG responses. This is the first study to demonstrate a statistically significant change in retinal electrical activity post-bevacizumab in patients with ARMD. This study demonstrates a method for utilizing mf-ERG to assess changes in retinal electrical activity and to assess the effectiveness of treatments such as bevacizumab.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.